A patient-focused, theory-guided approach to survey design identified barriers to and drivers of clinical trial participation.


Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
04 2021
Historique:
received: 05 05 2020
revised: 16 11 2020
accepted: 08 12 2020
pubmed: 19 12 2020
medline: 29 9 2021
entrez: 18 12 2020
Statut: ppublish

Résumé

Despite clear evidence showing that many clinical trials fail or are delayed because of poor patient recruitment, there is surprisingly little empirically supported guidance for trialists seeking to optimize their trial recruitment strategies. We propose that the challenges of recruitment can be better understood and addressed by thinking of research participation as one or more behaviors, subject to the same forces as other human behaviors. In this article, we describe an adaptable, behavioral theory-driven approach for designing pretrial surveys of the barriers and drivers relevant to trial participation. Instead of proposing a single survey instrument intended to be used uniformly across many situations, we propose that tailored surveys be informed by a common comprehensive, theory-guided development approach that ensures all domains potentially guiding participation are considered. We used the Theoretical Domains Framework (TDF), which organizes over 100 constructs known to be associated with behavior and behavior change into 14 domains that describe determinants of professional and patient health behaviors, to inform the development of tailored surveys about barriers to and drivers of clinical trial participation. After searching the literature for barriers and drivers to trial recruitment relevant to each of the TDF domains, we developed separate surveys for members of two national health charities (Canadian Breast Cancer Network, Huntington Society of Canada) to exemplify how the approach can be adapted across settings. We conducted think-aloud interviews with members of each group to maximize the clarity and usability of the surveys, elicited opinions about which barriers/drivers were relevant for each patient group, and identified additional barriers/drivers. Interviews proceeded iteratively with changes incorporated into subsequent interviews. Here, we describe our two target patient groups, as well as our process of modifying, adding, and deleting barrier/driver items for each group and across theoretical domains. We interviewed 8 women with a history of breast cancer from the Canadian Breast Cancer Network (48-65 year old) and 11 Huntington Disease community members (9 women) from the Huntington Society of Canada (26-70 year old). After the iterative development interviews, the breast cancer group had identified 38 barriers/drivers thought relevant to their participation in clinical trials across 12 TDF domains. The Huntington group identified 47 items across 13 TDF domains. Our patient-focused and theory-guided approach was able to identify a more comprehensive range of barriers to and drivers of trial participation than existing published tools. Our approach is also more broadly adaptable than such tools, in that it uses a theoretical framework and in-depth piloting to generate a set of items tailored to each specific clinical area, rather than a single set of items intended to be applicable to all situations. This theory-guided approach also enables more specific recruitment strategies to be developed once domain-specific barriers are known, potentially optimizing participation for a given trial and helping build a cumulative evidence of barriers/drivers and strategies for addressing them.

Identifiants

pubmed: 33338563
pii: S0895-4356(20)31217-8
doi: 10.1016/j.jclinepi.2020.12.013
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-115

Subventions

Organisme : CIHR
ID : PJT 169055
Pays : Canada

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Jamie C Brehaut (JC)

Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa Ontario, Canada, K1H 8L6; Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada, K1G 5Z3. Electronic address: jbrehaut@ohri.ca.

Kelly Carroll (K)

Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa Ontario, Canada, K1H 8L6.

Justin Presseau (J)

Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa Ontario, Canada, K1H 8L6; Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada, K1G 5Z3.

Dawn P Richards (DP)

Clinical Trials Ontario, 661 University Avenue, Suite 460, MaRS Centre, West Tower, Toronto, Canada M5G 1M1.

Jenn Gordon (J)

Canadian Breast Cancer Network, 331 Cooper St. Suite 602, Ottawa, Canada, K2P 0G5.

Angèle Bénard (A)

Huntington Society of Canada (HSC), 20 Erb Street West, Suite 801, Waterloo, Ontario, N2L1T2.

Natasha Hudek (N)

Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa Ontario, Canada, K1H 8L6.

Ian D Graham (ID)

Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa Ontario, Canada, K1H 8L6; Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada, K1G 5Z3.

Dean A Fergusson (DA)

Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa Ontario, Canada, K1H 8L6; Faculty of Medicine, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada, K1G 5Z3.

Susan Marlin (S)

Clinical Trials Ontario, 661 University Avenue, Suite 460, MaRS Centre, West Tower, Toronto, Canada M5G 1M1.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH